drugset / Trial / NCT06431256
Efficacy, Safety & Pharmacokinetic (PK) Study of HLD200 in Children Aged 4-5 Years With ADHD
Phase 3
Terminated
26 enrolled
Ironshore Pharmaceuticals and Development, Inc
Collegium Pharmaceutical, Inc. · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study will evaluate the efficacy, safety and pharmacokinetics of HLD200 (20 mg and 40 mg) in children aged 4 to 5 years with ADHD.
Timeline
- Start
- 2024-09-13
- Primary completion
- 2025-07-11
- Completion
- 2025-07-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Methylphenidate | Small molecule | 20 mg | — |
| Subject | Methylphenidate | Small molecule | 40 mg | — |